Saturday 17 October 2026
Export TPST’s income statement to Excel — free account
Tempest Therapeutics, Inc.
TPST Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.6% and free cash flow grew 67.0%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
0.62
0.02
−3.13%
Follow TPST
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 3,802.50 | 3,656.25 | 1,320.15 | 889.20 | 245.70 | 65.27 | 13.78 | 2.21 | 9.09 | 2.80 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 34,105.50 | 5,996.25 | 4,446.00 | 3,381.30 | 1,926.60 | 540.15 | 72.67 | 127.01 | 78.00 | 13.65 | |||||
| People | |||||||||||||||
| People | Employees | 118 | 36 | 34 | 38 | 13 | 17 | 19 | 17 | 25 | 4 | ||||
| Revenue/emp, $m | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 1 | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | (727.11) | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (82) | (85) | (27) | (45) | (19) | (28) | (36) | (29) | (42) | (26) | |||||
| EBT margin, % | (12,566.46) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (82) | (85) | (27) | (45) | (19) | (28) | (36) | (29) | (42) | (26) | |||||
| Depreciation | 3 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 59.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (7,482.76) | (62,703.32) | (3,427.41) | (633.62) | (533.72) | (97.14) | (40.18) | (24.84) | (19.51) | (6.33) | |||||
| Cash flow | (5,612.18) | (15,646.15) | (2,993.29) | (586.37) | (528.25) | (89.05) | (34.99) | (23.08) | (15.39) | (6.46) | |||||
| Capex | (235.09) | (3.08) | (4.56) | (5.65) | (1.39) | (0.46) | (0.63) | (0.14) | (0.20) | 0.00 | |||||
| Free cash flow | (5,847.27) | (15,649.23) | (2,997.85) | (592.02) | (529.64) | (89.51) | (35.62) | (23.22) | (15.59) | (6.46) | |||||
| Book value | 9,838.00 | 3,383.85 | 9,255.95 | 851.65 | 497.61 | 123.90 | 20.39 | 22.58 | 8.91 | 1.61 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | — | — | — | — | — | — | — | ||||
| P/S | 83.76 | — | — | — | — | — | — | — | — | — | |||||
| P/B | 0.51 | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | (91.41) | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | 0.93 | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (62) | (20) | (24) | (41) | (19) | (26) | (31) | (27) | (33) | (27) | ||||
| Capex | (3) | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | — | |||||
| Free cash flow | (64) | (20) | (24) | (42) | (19) | (26) | (32) | (28) | (33) | (27) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 103 | 16 | 74 | 59 | 17 | 49 | 26 | 31 | 17 | 5 | ||||
| Total debt | — | 1 | 1 | 0 | 2 | 15 | 10 | 6 | — | — | |||||
| Net debt | (114) | (17) | (77) | (63) | (17) | (37) | (21) | (33) | (30) | (8) | |||||
| Shareholders’ equity | 108 | 4 | 73 | 60 | 18 | 36 | 18 | 27 | 19 | 7 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (63.00) | (118.83) | (52.35) | (56.04) | (39.27) | (58.90) | (59.85) | (60.38) | (89.90) | (89.91) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (1,469.09) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (69.99) | 833.08 | 98.16 | (67.02) | 430.58 | 173.23 | (131.70) | (131.42) | (182.35) | (203.63) | |||||
Negative figures in brackets.
Fiscal years to Dec 2016 · latest quarter Sep 2017
Charts ten years each
Tempest Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PTN Palatin Technologies, Inc. | $11.6M | — (loss-making) | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| CLRB Cellectar Biosciences, Inc. | $11.2M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| INTS Intensity Therapeutics Inc. | $11.0M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PHIO Phio Pharmaceuticals Corp. | $10.8M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −58.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TPST Tempest Therapeutics, Inc. | $10.7M | — (loss-making) | — | −71.57% (below 0%: shrinking) | n/m | +67.04% (above 0%: growing) | 0.00% | 0.00% | |
| KPRX Kiora Pharmaceuticals, Inc. | $10.7M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GDTC CytoMed Therapeutics Limited | $10.3M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | Compare |
| BLRX BioLineRx Ltd. | $10.2M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | Compare |
| LTRN Lantern Pharma Inc. | $10.0M | — (loss-making) | — | — | n/m | +25.31% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $10.7M | — | — | −14.06% | — | −6.38% | 0.00% | 0.00% |
Tempest Therapeutics, Inc. (TPST) key facts
- Tempest Therapeutics, Inc. (TPST) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TPST traded at $0.62, a market capitalization of $10.7 million.
- Return on equity was −203.6% and debt-to-equity 0.00.
Tempest Therapeutics, Inc. (TPST) Latest News
No news at this impact. Lower the threshold for more.